about
Effect of postremission therapy before reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia in first complete remission.Allo-SCT conditioning for myelodysplastic syndrome and acute myeloid leukemia with clofarabine, cytarabine and ATG.A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia.Phase I study of oral clofarabine consolidation in adults aged 60 and older with acute myeloid leukemia.Protective effect of cytomegalovirus reactivation on relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia patients is influenced by conditioning regimenA phase I dose escalation study of oral bexarotene in combination with intravenous decitabine in patients with AML.A protease-resistant PML-RAR{alpha} has increased leukemogenic potential in a murine model of acute promyelocytic leukemiaExpression and function of PML-RARA in the hematopoietic progenitor cells of Ctsg-PML-RARA miceSequencing a mouse acute promyelocytic leukemia genome reveals genetic events relevant for disease progressionPhase I study of cladribine, cytarabine, granulocyte colony stimulating factor (CLAG regimen) and midostaurin and all-trans retinoic acid in relapsed/refractory AML.A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemiaPlasmacytoma-like post-transplantation lymphoproliferative disease occurring in a cardiac allograft: a case report and review of the literature.Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100.BIO5192, a small molecule inhibitor of VLA-4, mobilizes hematopoietic stem and progenitor cells.Management of the advanced phases of chronic myelogenous leukemia in the era of tyrosine kinase inhibitors.Dual receptor T cells mediate pathologic alloreactivity in patients with acute graft-versus-host diseaseA phase 1/2 study of chemosensitization with plerixafor plus G-CSF in relapsed or refractory acute myeloid leukemia.Oral valganciclovir versus ganciclovir as delayed pre-emptive therapy for patients after allogeneic hematopoietic stem cell transplant: a pilot trial (04-0274) and review of the literature.A phase II study of 5-day intravenous azacitidine in patients with myelodysplastic syndromes.Localization of human Cdc25C is regulated both by nuclear export and 14-3-3 protein binding.Exhaled nitric oxide correlates with experimental lung transplant rejection.Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation.Combination decitabine, arsenic trioxide, and ascorbic acid for the treatment of myelodysplastic syndrome and acute myeloid leukemia: a phase I study.Haploidentical transplantation using G-CSF-mobilized T-cell replete PBSCs and post-transplantation CY after non-myeloablative conditioning is safe and is associated with favorable outcomesPlerixaforA phase 1 study of concomitant high-dose lenalidomide and 5-azacitidine induction in the treatment of AML
P50
Q30408294-9B04206A-0A65-4786-A2F2-C7A639F460B9Q33382757-F1B12052-2064-40CC-A3A6-C8BF3F8809E7Q33392683-0FAB56C5-28BE-43B9-A6FB-0A34A295DF2AQ33412609-E0B66255-9B1D-4C86-AEED-1D15D804A6ABQ33645271-873A77E2-E597-446B-A31B-5121A2AC6670Q33939624-572EFD8C-879D-44FC-912F-98EF4123B09BQ34310547-B5AA6538-D162-4159-AD9E-F236F30395ECQ34441594-A4110984-58D5-4727-AA4F-6FA32761AC88Q34755408-7E0473E3-6A9C-4776-A77F-BB8D7EA0CF52Q35525811-BE0DFB6C-622C-4C0A-A1A3-47C259149A7DQ35953355-8CAB1DCE-4A68-4B13-A04F-9B5C458279EFQ36920282-CDAE71B7-05F3-47CA-A1DB-E476FB70C4EBQ37234638-9F25C918-BB36-4E3E-BC1A-AEA03BF7701FQ37306648-ECE86F91-F1AA-4013-81A9-A988EDCAE758Q37360559-2768244E-F2FA-42F0-8D83-FD7B34EE0220Q37383856-A4F4AF5A-6C06-43AE-8792-3003D023F090Q37737798-377FAEB2-EA2B-4D24-AC65-0D8C4D7F5792Q37957308-FB724A03-7DAD-442C-BDF6-313843E5BE46Q43299685-EDB0B1D4-10B8-4D97-AA95-64CE5F3D95F3Q43583330-01EC3BB3-C20E-4862-8DC4-3DDB94A8545BQ45864934-2A848C5E-74A6-47D7-A540-BBDC7E396F8CQ46415313-B0287468-517A-4982-BE14-E05F7804AACFQ53228060-8BA3B56E-3999-45D0-87B6-69D286F94CDCQ58050239-263FE260-189D-4C78-A6D9-DCD90FD7DC6BQ83265740-EC1AE93D-4699-48FD-A799-292A7D27621CQ84613053-465CB714-BF65-40B6-9730-67CC89F923B8
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Geoffrey L Uy
@ast
Geoffrey L Uy
@en
Geoffrey L Uy
@es
Geoffrey L Uy
@nl
type
label
Geoffrey L Uy
@ast
Geoffrey L Uy
@en
Geoffrey L Uy
@es
Geoffrey L Uy
@nl
prefLabel
Geoffrey L Uy
@ast
Geoffrey L Uy
@en
Geoffrey L Uy
@es
Geoffrey L Uy
@nl
P106
P1153
6508115716
P31
P496
0000-0002-7809-0996